Pfizer’s (PFE) Little White Lie

October 8, 2008 by Douglas A. McIntyre

R218533_855025US drug companies have a habit of misleading consumers and even physicians. It is a game they have played for decades. Usually they do not get caught. When they do a great cry goes up for reforming drug trials at the FDA and closer monitoring of pharma marketing practices.

Pfizer (PFE) is the latest alleged cheater. It could not leave well enough on sales of one of its most popular drugs so it may have decided to bend the rules.

According to The Wall Street Journal, "Pfizer Inc. marketers urged the suppression of medical studies that reached unfavorable conclusions about the effectiveness of the company’s big-selling drug Neurontin, according to internal Pfizer documents submitted in a lawsuit against the company." It amounted to a cover-up which probably began with the company consulting with Richard Nixon for advice.

As might be expected, Pfizer is fighting charges that it did anything wrong. It did not try to influence medical research. It did not burn documents of delete e-mails. No doctors were given envelops filled with $100 bills.

Pfizer’s problem is that no one will believe its defense. It has turned out that the alteration of drug testing or suppression of trial data has happened too many times before.

The trial information on vitamins and aspirin may even be wrong. Where was the FDA when those products came out?

Douglas A. McIntyre

Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)

Take the quiz below to get matched with a financial advisor today.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Take the retirement quiz right here.